The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 February 2026•

1 min read

XTL Biopharmaceuticals Faces Nasdaq Delisting Over 'Public Shell' Status

A world map in golden tones with overlaid financial charts showing a downward trend, a large blue arrow pointing down, and falling circuit boards and text. Two screens display NASDAQ data.

Key Facts

1XTL Biopharmaceuticals received a notice from Nasdaq stating it is no longer warranted for continued listing.

XTL Biopharmaceuticals Ltd. (XTLB) has received a formal notice from Nasdaq indicating that its shares are no longer suitable for continued listing. The Nasdaq Listing Qualifications Department based its decision on Rule 5101, categorizing the company as a "public shell" lacking sufficient core operations. This determination typically signals a lack of active business substance, which can severely impact investor confidence and stock liquidity. In response, XTL Biopharmaceuticals announced its intention to request a hearing to appeal the staff's determination. The request for a hearing will effectively stay the suspension and delisting process until a final decision is reached by the Nasdaq Hearings Panel. Despite the temporary stay, the company's future on the exchange remains uncertain as it attempts to prove its compliance with listing standards.